Elmfeldt D, Westerling S
Medical Department, Cardiovascular Research, AB Hässle, Mölndal.
Drugs. 1987;34 Suppl 3:132-5. doi: 10.2165/00003495-198700343-00028.
This review attempts to evaluate the benefit-risk balance of felodipine in the treatment of hypertension. Known positive and negative properties of felodipine are considered. Although accurate benefit-risk statements may be difficult even for old, well-established drugs it is concluded that felodipine appears to be an effective and well tolerated new antihypertensive drug. The reduction in blood pressure during felodipine treatment has been superior to that seen with established antihypertensive drugs in controlled studies.
本综述旨在评估非洛地平治疗高血压的获益-风险平衡。文中考虑了非洛地平已知的阳性和阴性特性。尽管即便对于使用已久的成熟药物,准确阐述其获益-风险情况也可能存在困难,但得出的结论是,非洛地平似乎是一种有效且耐受性良好的新型抗高血压药物。在对照研究中,非洛地平治疗期间的血压降低幅度优于已有的抗高血压药物。